IN THE CLAIMS

Please amend the claims as follows:

Claim 1 (Original): A preventive or therapeutic agent for pathological conditions caused by reduced production of erythropoietin, comprising as an active ingredient, a cyclic amine compound represented by the following formula (1):



(1)

wherein,

R^1, R^2 and R^3 each independently represent a hydrogen atom, a halogen atom, or hydroxy, alkyl, halogen-substituted alkyl, alkoxy, alkylthio, carboxyl, alkoxycarbonyl or alkanoyl group;

W^1 and W^2 each independently represent N or CH;

X represents O, NR^4, $CONR^4$ or NR^4CO;

R^4 each represents a hydrogen atom, or an alkyl, alkenyl, alkynyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted aralkyl, or substituted or unsubstituted heteroaralkyl group; and

l, m and n each represents a number of 0 or 1, or a salt thereof or a solvate thereof.

Claim 2 (Original): The preventive or therapeutic agent according to claim 1, wherein R^1, R^2 and R^3 are each a hydrogen atom, a halogen atom, a hydroxy group, a C_1-C_8-alkyl group, a halogen-substituted C_1-C_8-alkyl, an alkoxy group having a C_1-C_8-alkyl group, an alkylthio group having a C_1-C_8-alkyl group, a carboxyl group, an alkoxycarbonyl group having a C_1-C_6-alkyl group, or an alkanoyl group having a C_1-C_6-alkyl group.

Claim 3 (Original): The preventive or therapeutic agent according to claim 1, wherein R^4 each represents a hydrogen atom, a C_1-C_8-alkyl group, C_3-C_8-alkenyl group, C_3-C_8-alkynyl group, substituted or unsubstituted C_6-C_{14}-aryl group, substituted or unsubstituted heteroaryl group having 5- or 6-membered ring containing 1-4 nitrogen atoms, substituted or unsubstituted C_6-C_{14}-aryl-C_1-C_6-alkyl group, or C_1-C_6-alkyl group having heteroaryl group having 5- or 6-membered ring containing 1-4 nitrogen atoms.

Claim 4 (Original): The preventive or therapeutic agent according to claim 3, wherein in R^4, the substituent of an aryl group, an aryl group of aralkyl group, heteroaryl group, or heteroaryl group of heteroaralkyl group is 1-3 groups selected from the group consisting of alkyl group, alkoxy group, alkylthio group, a halogen atom, a nitro group, an amino group, an acetylamino group, trifluoromethyl group and alkylenedioxy group.

Claim 5 (Original): The preventive or therapeutic agent according to claim 1, wherein the active ingredient is

4-[N-(4-methoxyphenyl)-N-[[5-(3,4,5-trimethoxyphenyl)pyridine-3-yl]methyl]amino]-1-[[2-(3,4,5-trimethoxyphenyl)pyridine-4-yl]methyl]piperidine;

4-[N-(3,5-dimethoxyphenyl)-N-[[2-(3,4,5-trimethoxyphenyl)piridine-4-yl]methyl]amino]-1-[[2-(3,4,5-trimethoxyphenyl)piridine-4-yl]methyl]piperidine;

4-[N-(3,4-methylenedioxyphenyl)-N-[[2-(3,4,5-trimethoxyphenyl)piridine-4-yl]methyl]amino]-1-[[2-(3,4,5-trimethoxyphenyl)piridine-4-yl]methyl]piperidine;

4-[N-methyl-N-[[2-(3,4,5-trimethoxyphenyl)piridine-4-yl]methyl]amino]-1-[[2-(3,4,5-trimethoxyphenyl)piridine-4-yl]methyl]piperidine;

4-[N-(4-(methylthio)phenyl)-N-[[5-(3,4,5-tromethoxyphenyl)piridine-3-yl]methyl]amino]-1-[[2-(3,4,5-tromethoxyphenyl)piridine-4-yl]methyl]piperidine; or a salt thereof.

Claim 6 (Original): A preventive or therapeutic agent for anemia, comprising as an active ingredient, a cyclic amine compound represented by the following formula (1):



(1)

wherein,

R^1, R^2 and R^3 each independently represent a hydrogen atom, a halogen atom, or hydroxy, alkyl, halogen-substituted alkyl, alkoxy, alkylthio, carboxyl, alkoxycarbonyl or alkanoyl group;

W^1 and W^2 each independently represent N or CH;

X represents O, NR^4, $CONR^4$ or NR^4CO;

R^4 each represents a hydrogen atom, or an alkyl, alkenyl, alkynyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted aralkyl, or substituted or unsubstituted heteroaralkyl group; and

l, m and n each represents a number of 0 or 1, or a salt thereof or a solvate thereof.

Claim 7 (Original): The preventive or therapeutic agent according to claim 6, wherein R^1, R^2 and R^3 are each a hydrogen atom, a halogen atom, a hydroxy group, a C_1-C_8-alkyl group, a halogen-substituted C_1-C_8-alkyl, an alkoxy group having a C_1-C_8-alkyl group, an alkylthio group having a C_1-C_8-alkyl group, a carboxyl group, an alkoxycarbonyl group having a C_1-C_6-alkyl group, or an alkanoyl group having a C_1-C_6-alkyl group.

Claim 8 (Original): The preventive or therapeutic agent according to claim 6, wherein R^4 each represents a hydrogen atom, a C_1-C_8-alkyl group, C_3-C_8-alkenyl group, C_3-C_8-alkynyl group, substituted or unsubstituted C_6-C_{14}-aryl group, substituted or unsubstituted heteroaryl group having 5- or 6-membered ring containing 1-4 nitrogen atoms, substituted or unsubstituted C_6-C_{14}-aryl-C_1-C_6-alkyl group, or C_1-C_6-alkyl group having heteroaryl group having 5- or 6-membered ring containing 1-4 nitrogen atoms.

Claim 9 (Original): The preventive or therapeutic agent according to claim 8, wherein in R^4, the substituent of an aryl group, an aryl group of aralkyl group, heteroaryl group, or heteroaryl group of heteroaralkyl group is 1-3 groups selected from the group consisting of alkyl group, alkoxy group, alkylthio group, a halogen atom, a nitro group, an amino group, an acetylamino group, trifluoromethyl group and alkylenedioxy group.

Claim 10 (Original): The preventive or therapeutic agent according to claim 6, wherein the active ingredient is

4-[N-(4-methoxyphenyl)-N-[[5-(3,4,5-trimethoxyphenyl)pyridine-3-yl]methyl]amino]-1-[[2-(3,4,5-trimethoxyphenyl)pyridine-4-yl]methyl]piperidine;

4-[N-(3,5-dimethoxyphenyl)-N-[[2-(3,4,5-trimethoxyphenyl)piridine-4-yl]methyl]amino]-1-[[2-(3,4,5-trimethoxyphenyl)piridine-4-yl]methyl]piperidine;

4-[N-(3,4-methylenedioxyphenyl)-N-[[2-(3,4,5-trimethoxyphenyl)piridine-4-yl]methyl]amino]-1-[[2-(3,4,5-trimethoxyphenyl)piridine-4-yl]methyl]piperidine;

4-[N-methyl-N-[[2-(3,4,5-trimethoxyphenyl)piridine-4-yl]methyl]amino]-1-[[2-(3,4,5-trimethoxyphenyl)piridine-4-yl]methyl]piperidine;

4-[N-(4-(methylthio)phenyl)-N-[[5-(3,4,5-tromethoxyphenyl)piridine-3-yl]methyl]amino]-1-[[2-(3,4,5-tromethoxyphenyl)piridine-4-yl]methyl]piperidine; or a salt thereof.

Claim 11 (Original): A preventive or therapeutic agent for chronic anemia, renal anemia, anaplastic anemia or pure red cell aplasia, comprising as an active ingredient, a cyclic amine compound represented by the following formula (1):



(1)

wherein,

R^1, R^2 and R^3 each independently represent a hydrogen atom, a halogen atom, or hydroxy, alkyl, halogen-substituted alkyl, alkoxy, alkylthio, carboxyl, alkoxycarbonyl or alkanoyl group;

W^1 and W^2 each independently represent N or CH;

X represents O, NR^4, $CONR^4$ or NR^4CO;

R^4 each represents a hydrogen atom, or an alkyl, alkenyl, alkynyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted aralkyl, or substituted or unsubstituted heteroaralkyl group; and

l, m and n each represents a number of 0 or 1, or a salt thereof or a solvate thereof.

Claim 12 (Original): The preventive or therapeutic agent according to claim 11, wherein R^1, R^2 and R^3 are each a hydrogen atom, a halogen atom, a hydroxy group, a C_1-C_8-alkyl group, a halogen-substituted C_1-C_8-alkyl, an alkoxy group having a C_1-C_8-alkyl group, an alkylthio group having a C_1-C_8-alkyl group, a carboxyl group, an alkoxycarbonyl group having a C_1-C_6-alkyl group, or an alkanoyl group having a C_1-C_6-alkyl group.

Claim 13 (Original): The preventive or therapeutic agent according to claim 11, wherein R^4 each represents a hydrogen atom, a C_1-C_8-alkyl group, C_3-C_8-alkenyl group, C_3-C_8-alkynyl group, substituted or unsubstituted C_6-C_{14}-aryl group, substituted or unsubstituted heteroaryl group having 5- or 6-membered ring containing 1-4 nitrogen atoms, substituted or unsubstituted C_6-C_{14}-aryl-C_1-C_6-alkyl group, or C_1-C_6-alkyl group having heteroaryl group having 5- or 6-membered ring containing 1-4 nitrogen atoms.

Claim 14 (Original): The preventive or therapeutic agent according to claim 13, wherein in R^4, the substituent of an aryl group, an aryl group of aralkyl group, heteroaryl group, or heteroaryl group of heteroaralkyl group is 1-3 groups selected from the group consisting of alkyl group, alkoxy group, alkylthio group, a halogen atom, a nitro group, an amino group, an acetylamino group, trifluoromethyl group and alkylenedioxy group.

Claim 15 (Original): The preventive or therapeutic agent according to claim 11, wherein the active ingredient is 4-[N-(4-methoxyphenyl)-N-[[5-(3,4,5-trimethoxyphenyl)pyridine-3-yl]methyl]amino]-1-[[2-(3,4,5-trimethoxyphenyl)pyridine-4-yl]methyl]piperidine;

4-[N-(3,5-dimethoxyphenyl)-N-[[2-(3,4,5-trimethoxyphenyl)piridine-4-yl]methyl]amino]-1-[[2-(3,4,5-trimethoxyphenyl)piridine-4-yl]methyl]piperidine;

4-[N-(3,4-methylenedioxyphenyl)-N-[[2-(3,4,5-trimethoxyphenyl)piridine-4-yl]methyl]amino]-1-[[2-(3,4,5-trimethoxyphenyl)piridine-4-yl]methyl]piperidine;

4-[N-methyl-N-[[2-(3,4,5-trimethoxyphenyl)piridine-4-yl]methyl]amino]-1-[[2-(3,4,5-trimethoxyphenyl)piridine-4-yl]methyl]piperidine;

4-[N-(4-(methylthio)phenyl)-N-[[5-(3,4,5-tromethoxyphenyl)piridine-3-yl]methyl]amino]-1-[[2-(3,4,5-tromethoxyphenyl)piridine-4-yl]methyl]piperidine; or a salt thereof.

Claims 16-30 (Canceled).

Claim 31 (Original): A method of treating pathological conditions caused by reduced production of erythropoietin, comprising administering an effective amount of a cyclic amine compound represented by the following formula (1):



(1)

wherein,

R^1, R^2 and R^3 each independently represent a hydrogen atom, a halogen atom, or hydroxy, alkyl, halogen-substituted alkyl, alkoxy, alkylthio, carboxyl, alkoxycarbonyl or alkanoyl group;

W^1 and W^2 each independently represent N or CH;

X represents O, NR^4, $CONR^4$ or NR^4CO;

R^4 each represents a hydrogen atom, or an alkyl, alkenyl, alkynyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted aralkyl, or substituted or unsubstituted heteroaralkyl group; and

l, m and n each represents a number of 0 or 1, or a salt thereof or a solvate thereof.

Claim 32 (Original): The method according to claim 31, wherein R^1, R^2 and R^3 are each a hydrogen atom, a halogen atom, a hydroxy group, a C_1-C_8-alkyl group, a halogen-

substituted C_1-C_8-alkyl, an alkoxy group having a C_1-C_8-alkyl group, an alkylthio group having a C_1-C_8-alkyl group, a carboxyl group, an alkoxycarbonyl group having a C_1-C_6-alkyl group, or an alkanoyl group having a C_1-C_6-alkyl group.

Claim 33 (Original): The method according to claim 31, wherein R^4 each represents a hydrogen atom, a C_1-C_8-alkyl group, C_3-C_8-alkenyl group, C_3-C_8-alkynyl group, substituted or unsubstituted C_6-C_{14}-aryl group, substituted or unsubstituted heteroaryl group having 5- or 6-membered ring containing 1-4 nitrogen atoms, substituted or unsubstituted C_6-C_{14}-aryl-C_1-C_6-alkyl group, or C_1-C_6-alkyl group having heteroaryl group having 5- or 6-membered ring containing 1-4 nitrogen atoms.

Claim 34 (Original): The method according to claim 33, wherein in R^4, the substituent of an aryl group, an aryl group of aralkyl group, heteroaryl group, or heteroaryl group of heteroaralkyl group is 1-3 groups selected from the group consisting of alkyl group, alkoxy group, alkylthio group, a halogen atom, a nitro group, an amino group, an acetylamino group, trifluoromethyl group and alkylenedioxy group.

Claim 35 (Original): The method according to claim 31, wherein the active ingredient is

4-[N-(4-methoxyphenyl)-N-[[5-(3,4,5-trimethoxyphenyl)pyridine-3-yl]methyl]amino]-1-[[2-(3,4,5-trimethoxyphenyl)pyridine-4-yl]methyl]piperidine;

4-[N-(3,5-dimethoxyphenyl)-N-[[2-(3,4,5-trimethoxyphenyl)piridine-4-yl]methyl]amino]-1-[[2-(3,4,5-trimethoxyphenyl)piridine-4-yl]methyl]piperidine;

4-[N-(3,4-methylenedioxyphenyl)-N-[[2-(3,4,5-trimethoxyphenyl)piridine-4-yl]methyl]amino]-1-[[2-(3,4,5-trimethoxyphenyl)piridine-4-yl]methyl]piperidine;

4-[N-methyl-N-[[2-(3,4,5-trimethoxyphenyl)piridine-4-yl]methyl]amino]-1-[[2-(3,4,5-trimethoxyphenyl)piridine-4-yl]methyl]piperidine;

4-[N-(4-(methylthio)phenyl)-N-[[5-(3,4,5-tromethoxyphenyl)piridine-3-yl]methyl]amino]-1-[[2-(3,4,5-tromethoxyphenyl)piridine-4-yl]methyl]piperidine; or a salt thereof.

Claim 36 (Original): A method of treating anemia, comprising administering an effective amount of a cyclic amine compound represented by the following formula (1):



(1)

wherein,

R^1, R^2 and R^3 each independently represent a hydrogen atom, a halogen atom, or hydroxy, alkyl, halogen-substituted alkyl, alkoxy, alkylthio, carboxyl, alkoxycarbonyl or alkanoyl group;

W^1 and W^2 each independently represent N or CH;

X represents O, NR^4, $CONR^4$ or NR^4CO;

R^4 each represents a hydrogen atom, or an alkyl, alkenyl, alkynyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted aralkyl, or substituted or unsubstituted heteroaralkyl group; and

l, m and n each represents a number of 0 or 1, or a salt thereof or a solvate thereof.

Claim 37 (Original): The method according to claim 36, wherein R^1, R^2 and R^3 are each a hydrogen atom, a halogen atom, a hydroxy group, a C_1-C_8-alkyl group, a halogen-substituted C_1-C_8-alkyl, an alkoxy group having a C_1-C_8-alkyl group, an alkylthio group

having a C_1-C_8-alkyl group, a carboxyl group, an alkoxycarbonyl group having a C_1-C_6-alkyl group, or an alkanoyl group having a C_1-C_6-alkyl group.

Claim 38 (Original): The method according to claim 36, wherein R^4 each represents a hydrogen atom, a C_1-C_8-alkyl group, C_3-C_8-alkenyl group, C_3-C_8-alkynyl group, substituted or unsubstituted C_6-C_{14}-aryl group, substituted or unsubstituted heteroaryl group having 5- or 6-membered ring containing 1-4 nitrogen atoms, substituted or unsubstituted C_6-C_{14}-aryl-C_1-C_6-alkyl group, or C_1-C_6-alkyl group having heteroaryl group having 5- or 6-membered ring containing 1-4 nitrogen atoms.

Claim 39 (Original): The method according to claim 38, wherein in R^4, the substituent of an aryl group, an aryl group of aralkyl group, heteroaryl group, or heteroaryl group of heteroaralkyl group is 1-3 groups selected from the group consisting of alkyl group, alkoxy group, alkylthio group, a halogen atom, a nitro group, an amino group, an acetylamino group, trifluoromethyl group and alkylenedioxy group.

Claim 40 (Original): The method according to claim 36, wherein the active ingredient is

4-[N-(4-methoxyphenyl)-N-[[5-(3,4,5-trimethoxyphenyl)pyridine-3-yl]methyl]amino]-1-[[2-(3,4,5-trimethoxyphenyl)pyridine-4-yl]methyl]piperidine;

4-[N-(3,5-dimethoxyphenyl)-N-[[2-(3,4,5-trimethoxyphenyl)piridine-4-yl]methyl]amino]-1-[[2-(3,4,5-trimethoxyphenyl)piridine-4-yl]methyl]piperidine;

4-[N-(3,4-methylenedioxyphenyl)-N-[[2-(3,4,5-trimethoxyphenyl)piridine-4-yl]methyl]amino]-1-[[2-(3,4,5-trimethoxyphenyl)piridine-4-yl]methyl]piperidine;

4-[N-methyl-N-[[2-(3,4,5-trimethoxyphenyl)piridine-4-yl]methyl]amino]-1-[[2-(3,4,5-trimethoxyphenyl)piridine-4-yl]methyl]piperidine;

4-[N-(4-(methylthio)phenyl)-N-[[5-(3,4,5-tromethoxyphenyl)piridine-3-yl]methyl]amino]-1-[[2-(3,4,5-tromethoxyphenyl)piridine-4-yl]methyl]piperidine; or a salt thereof.

Claim 41 (Original): A method of treating chronic anemia, renal anemia, aplastic anemia, or pure red cell aplasia, comprising administering an effective amount of a cyclic amine compound represented by the following formula (1):



(1)

wherein,

R^1, R^2 and R^3 each independently represent a hydrogen atom, a halogen atom, or hydroxy, alkyl, halogen-substituted alkyl, alkoxy, alkylthio, carboxyl, alkoxycarbonyl or alkanoyl group;

W^1 and W^2 each independently represent N or CH;

X represents O, NR^4, $CONR^4$ or NR^4CO;

R^4 each represents a hydrogen atom, or an alkyl, alkenyl, alkynyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted aralkyl, or substituted or unsubstituted heteroaralkyl group; and

l, m and n each represents a number of 0 or 1, or a salt thereof or a solvate thereof.

Claim 42 (Original): The method according to claim 41, wherein R^1, R^2 and R^3 are each a hydrogen atom, a halogen atom, a hydroxy group, a C_1-C_8-alkyl group, a halogen-

substituted C_1-C_8-alkyl, an alkoxy group having a C_1-C_8-alkyl group, an alkylthio group having a C_1-C_8-alkyl group, a carboxyl group, an alkoxycarbonyl group having a C_1-C_6-alkyl group, or an alkanoyl group having a C_1-C_6-alkyl group.

Claim 43 (Original): The method according to claim 41, wherein R^4 each represents a hydrogen atom, a C_1-C_8-alkyl group, C_3-C_8-alkenyl group, C_3-C_8-alkynyl group, substituted or unsubstituted C_6-C_{14}-aryl group, substituted or unsubstituted heteroaryl group having 5- or 6-membered ring containing 1-4 nitrogen atoms, substituted or unsubstituted C_6-C_{14}-aryl-C_1-C_6-alkyl group, or C_1-C_6-alkyl group having heteroaryl group having 5- or 6-membered ring containing 1-4 nitrogen atoms.

Claim 44 (Original): The method according to claim 43, wherein in R^4, the substituent of an aryl group, an aryl group of aralkyl group, heteroaryl group, or heteroaryl group of heteroaralkyl group is 1-3 groups selected from the group consisting of alkyl group, alkoxy group, alkylthio group, a halogen atom, a nitro group, an amino group, an acetylamino group, trifluoromethyl group and alkylenedioxy group.

Claim 45 (Original): The method according to claim 41, wherein the active ingredient is

4-[N-(4-methoxyphenyl)-N-[[5-(3,4,5-trimethoxyphenyl)pyridine-3-yl]methyl]amino]-1-[[2-(3,4,5-trimethoxyphenyl)pyridine-4-yl]methyl]piperidine;

4-[N-(3,5-dimethoxyphenyl)-N-[[2-(3,4,5-trimethoxyphenyl)piridine-4-yl]methyl]amino]-1-[[2-(3,4,5-trimethoxyphenyl)piridine-4-yl]methyl]piperidine;

4-[N-(3,4-methylenedioxyphenyl)-N-[[2-(3,4,5-trimethoxyphenyl)piridine-4-yl]methyl]amino]-1-[[2-(3,4,5-trimethoxyphenyl)piridine-4-yl]methyl]piperidine;

4-[N-methyl-N-[[2-(3,4,5-trimethoxyphenyl)piridine-4-yl]methyl]amino]-1-[[2-(3,4,5-trimethoxyphenyl)piridine-4-yl]methyl]piperidine;

4-[N-(4-(methylthio)phenyl)-N-[[5-(3,4,5-tromethoxyphenyl)piridine-3-yl]methyl]amino]-1-[[2-(3,4,5-tromethoxyphenyl)piridine-4-yl]methyl]piperidine; or a salt thereof.